Polymers for Solubility Enhancement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Polymers for Solubility Enhancement


Pharmaceutical Technology Europe
Volume 26, Issue 8, pp. 30
PharmTech Europe 25th Anniversary
DSGpro/Getty Images;
Art direction: Dan Ward

Surveying the Landscape of Solid-Dosage Manufacturing

Experts take a look at the journey travelled thus far and where pharmaceutical manufacturing is heading over the next decade.

An increasing number of new chemical entities (NCEs) have poor aqueous solubility requiring the use of technologies to enable sufficient oral bioavailability of these NCEs following administration. The use of amorphous solid dispersions (ASDs) to increase the apparent solubility of an NCE is one area that is growing rapidly. The formation of ASDs is typically done by using spray drying or hot melt extrusion (HME) to disperse the active ingredient into a polymer matrix.

<

Pharmaceutical Technology Europe
25th Anniversary Issue


Quality by Design—a Fundamental Paradigm Shift in Pharmaceutical Manufacturing

Tableting—a Focus for Continuous Improvement

Continuous Manufacturing—the Future of Pharmaceutical Manufacturing

Trends in Tablet Tooling

Polymers for Solubility Enhancement

A number of factors will determine if spray drying or HME is the preferred route for formulation, including thermal stability of the NCE, organic solvent dissolution and excipient compatibility. For the excipient, important performance factors include glass transition temperature, thermal stability, dissolution profiles in organic solvents and optimal solubilisation of the API in the ASD. Examples of excipients used in the production of ASDs include polyglycols, such as polyethylene glycol (PEG) and polyethylene oxide (PEO); polyvinyl polymers including polyvinylpyrrolidone (PVP) and polvinylpyrrolidone-polyvinylacetate copolymer (PVP-VA); acrylates and methacrylate (co-)polymers; and cellulosics including hypromellose (HPMC) and hydroxypropylmethylcellulose acetate succinate (HPMCAS).

The ability to formulate robust and stable ASDs has been aided by the recent development of functional excipients designed specifically for ASD technologies. To ensure robustness of formulation, excipients are being designed with quality-by-design (QbD) principles. This approach ensures that the impact that excipient variation has on the performance of a formulation is understood and can be controlled through proper excipient selection and specification.

In addition, excipients designed specifically for HME are being developed. These excipients, such as Soluplus from BASF and AFFINISOL HPMC from Dow enable HME by having lower glass transition temperatures and a broad thermal processing range. For spray drying, advancement has been seen in the utility of excipients by improving the solution throughput in spray dryers. An example is the introduction of AFFINISOL High Productivity HPMCAS for spray drying, in which the solid loading in a spray-drying solution can be increased by more than 1.5 times without the loss of solubility enhancement in the formulation. The rapid advancement in functional excipients and processes now designed for solubility enhancement through the formation of ASDs makes ASDs a more conventional approach for poorly soluble compounds.

AFFINISOL is a trademark of The Dow Chemical Company.
Soluplus is a trademark of BASF SE.

 

William Porter III
William Porter III

About the Author
William Porter III, is senior chemist, R&D, at Dow Pharma & Food Solutions.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here